Elgammal, YehiaSalama, Ehab A.Seleem, Mohamed N.2023-11-302023-11-302023-05-170066-4804https://hdl.handle.net/10919/116714Candida auris represents an urgent health threat. Here, we identified atazanavir as a potent drug capable of resensitizing C. auris clinical isolates to the activity of azole antifungals. Atazanavir was able to significantly inhibit the efflux pumps, glucose transport, and ATP synthesis of all tested isolates of C. auris. In addition, the combination of itraconazole with atazanavir-ritonavir significantly reduced the burden of azole-resistant C. auris in murine kidneys by 1.3 log10 (95%), compared to itraconazole alone.5 page(s)application/pdfenIn CopyrightHIV protease inhibitorsCandida aurisatazanavirazole resistanceefflux pumpsin vivo disseminated candidiasis mouse modelAnimalsMiceCandidaAzolesFluconazoleItraconazoleAntifungal AgentsMicrobial Sensitivity TestsDrug Resistance, FungalAtazanavir SulfateCandida aurisArticle - Refereedhttps://doi.org/10.1128/aac.01631-22675Seleem, Mohamed [0000-0003-0939-0458]370929911098-6596